Sanofi, Novo Slump as Diabetes Moves on From Insulin Tradition

Sanofi offered a bleak assessment of its outlook for diabetes sales on Thursday while rival Novo Nordisk A/S sounded a more upbeat note. Both stocks took a beating.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.